304 related articles for article (PubMed ID: 35963179)
1. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Swain SM; Nishino M; Lancaster LH; Li BT; Nicholson AG; Bartholmai BJ; Naidoo J; Schumacher-Wulf E; Shitara K; Tsurutani J; Conte P; Kato T; Andre F; Powell CA
Cancer Treat Rev; 2022 May; 106():102378. PubMed ID: 35430509
[TBL] [Abstract][Full Text] [Related]
4. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
[TBL] [Abstract][Full Text] [Related]
6. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M
ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548
[TBL] [Abstract][Full Text] [Related]
7. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract][Full Text] [Related]
8. Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective.
Henning JW; Brezden-Masley C; Gelmon K; Chia S; Shapera S; McInnis M; Rayson D; Asselah J
Curr Oncol; 2023 Aug; 30(9):8019-8038. PubMed ID: 37754497
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients.
Wekking D; Porcu M; Pellegrino B; Lai E; Mura G; Denaro N; Saba L; Musolino A; Scartozzi M; Solinas C
ESMO Open; 2023 Dec; 8(6):102043. PubMed ID: 37951130
[TBL] [Abstract][Full Text] [Related]
10. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
[TBL] [Abstract][Full Text] [Related]
11. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
12. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract][Full Text] [Related]
13. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
Rugo HS; Crossno CL; Gesthalter YB; Kelley K; Moore HB; Rimawi MF; Westbrook KE; Buys SS
JCO Oncol Pract; 2023 Aug; 19(8):539-546. PubMed ID: 37207306
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
Shitara K
Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Nonomiya Y; Nakayama I; Kobayashi K; Amakawa Y; Shibata N; Soejima A; Kawakami K; Shimizu H; Takahari D; Kawai S; Hara F; Takano T; Yamaguchi K; Yamaguchi M
Biol Pharm Bull; 2024; 47(2):411-416. PubMed ID: 38346748
[TBL] [Abstract][Full Text] [Related]
17. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract][Full Text] [Related]
18. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
